MedWatch

Analyst: Next sclerosis trigger awaits

Multiple sclerosis could be the next major medical adventure for Danish biotech company Genmab, but one important question has yet to be answered.

Foto: BORCH ULRICH

Last week, Genmab announced some great news. The Danish biotech company, mostly known for its cancer drugs, and its partner GlaxoSmithKline (GSK) presented promising data for the drug ofatumumab in the treatment of relapsing-remitting multiple sclerosis (RRMS), the most common form of the debilitating disease.

But one crucial question has yet to be answered before the sclerosis adventure can really kick off.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier